Citizens Reiterates Buy Rating on Kura Oncology, Inc.
Citizens maintains buy rating on Kura with a $24 target.
Key Points
- Citizens reiterated its buy rating for Kura Oncology, Inc. (KURA) with a price target of $24 on June 15, 2026.
- Shares of Kura traded at $9.05, with a market cap of about $847 million, and a 52-week range between $5.45 and $12.49.
- Insiders including Thomas Malley and Faheem Hasnain bought 35,000 shares each on June 4, 2026, indicating insider confidence.
On June 15, 2026, Citizens reiterated its buy rating on Kura Oncology, Inc. (NasdaqGS: KURA) with a price target of $24. Kura's stock was trading at $9.05, giving it a market cap of approximately $847 million.
Kura Oncology Stock Snapshot
Shares of NasdaqGS:KURA were trading near $9.05. Kura Oncology has a market capitalization of about $847 million and a beta of 0.364, indicating lower volatility compared to the market. The stock's 52-week low is $5.45, and its high is $12.49, with a 50-day moving average of $9.29 and a 200-day moving average of $9.34. The company has a strong current ratio of 6.15 and a quick ratio of 5.86, with a debt-to-equity ratio of 22.5.
Recent Earnings
Kura Oncology reported revenue of $71.64 million, with a revenue growth rate of 29.5%. Despite the growth, the company is not yet profitable, with a net margin of 0% and a return on equity of -124.7%. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Kura Oncology, Inc.
On June 4, 2026, several insiders at Kura Oncology, including Thomas Malley and Faheem Hasnain, bought 35,000 shares each. These purchases were not part of planned transactions, suggesting a show of confidence in the company's future.
Analysts Set New Price Targets
On June 15, 2026, Citizens reiterated its buy rating for Kura Oncology with a $24 price target. Other analysts have also shown support; Lake Street initiated coverage with a buy rating and a $23 target on April 14, 2026, and Mizuho maintained a buy rating with a $25 target on March 24, 2026. The consensus among analysts is a strong buy, with a target mean price of $31.17.
About Kura Oncology
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California. It focuses on developing medicines for cancer treatment. The company is working on several promising projects, including KOMZIFTI, a menin inhibitor, and Darlifarnib, which is in Phase 1 trials for solid tumor indications. Dr. Troy Edward Wilson is the CEO, leading a team of about 260 employees.
Bottom Line
Citizens' reiterated buy rating with a $24 target highlights ongoing confidence in Kura Oncology's potential. Investors keep a close eye on such ratings as they provide insight into analysts' views on the company's growth prospects. However, it's important to remember that these ratings reflect opinions and should be considered as part of a broader investment strategy.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.